Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C virus therapy to date.

Graham Foster1, Philippe Mathurin

  • 1Queen Mary Hospital, University of London, London, UK. g.r.foster@qmul.ac.uk

Antiviral Therapy
|April 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updates in clinical science: Alcohol-related hepatitis.

Journal of hepatology·2026
Same author

Trends in mortality and years of life lost among patients with cirrhosis and hepatocellular carcinoma in France, 2011-2023: a nationwide retrospective population-based study.

The Lancet regional health. Europe·2026
Same author

Implementing sustainable liver health in Europe: a second EASL-Lancet Commission.

Lancet (London, England)·2026
Same author

Success of transition to adult care in patients with pediatric-onset chronic liver disease.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Alcohol-related hepatitis induces a specific fibrosis profile through YAP activation in myofibroblasts.

JHEP reports : innovation in hepatology·2025
Same author

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Journal of hepatology·2025
Same journal

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.

Antiviral therapy·2026
Same journal

Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.

Antiviral therapy·2026
Same journal

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe - a physician survey.

Antiviral therapy·2026
Same journal

It's about time: The association between abacavir and cardiovascular disease.

Antiviral therapy·2026
Same journal

Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study.

Antiviral therapy·2026
Same journal

Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage <i>In silico</i> study.

Antiviral therapy·2025
See all related articles

Chronic hepatitis C treatments have advanced significantly, with pegylated interferons and ribavirin now the standard of care. This review details these therapies for cirrhosis and liver cancer prevention.

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Pharmacology and Therapeutics

Background:

  • Chronic hepatitis C is a leading cause of cirrhosis and hepatocellular cancer globally.
  • Significant research has focused on understanding and treating hepatitis C virus (HCV) infection.

Purpose of the Study:

  • To review therapeutic advances in chronic hepatitis C treatment over the last decade.
  • To discuss the properties, pharmacokinetics, viral kinetics, and side effects of HCV treatments.

Main Methods:

  • Literature review of scientific publications on hepatitis C therapies.
  • Analysis of treatment options, including pegylated interferons and ribavirin.
  • Evaluation of combination therapy as the current standard of care.

Main Results:

Related Experiment Videos

  • Pegylated interferons and ribavirin represent major therapeutic advancements.
  • Combination therapy with pegylated interferon and ribavirin is the established standard of care.
  • Understanding of physical properties, pharmacokinetics, and viral kinetics has improved treatment efficacy.

Conclusions:

  • Therapeutic options for chronic hepatitis C have substantially improved.
  • Pegylated interferon and ribavirin combination therapy offers an effective treatment strategy.
  • Continued research is vital for further refining hepatitis C management and reducing disease burden.